CNN via

CNN via is a common attribution for articles that are originally published on CNN and then republished on other platforms. The actual author's name is not provided, which can make it difficult to provide a detailed biography or assess potential conflicts of interest. However, the content of the articles is typically produced by CNN's team of professional journalists and editors, who are expected to adhere to the network's editorial standards and practices.

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

American Cancer Society Expands Lung Cancer Screening Guidelines; Other Health Updates

Broke On: Thursday, 02 November 2023 The American Cancer Society has updated its lung cancer screening guidelines to include nearly 5 million more adults who smoke or used to smoke. The new guidelines recommend annual lung cancer screenings for individuals aged 50 to 80 years old who have a 20-year or greater pack-year history. The update is expected to increase the number of eligible patients by about 37%. Insurance coverage for lung cancer screenings based on this updated guideline may vary. Recent medical studies and trials have highlighted the effectiveness of Selpercatinib vs Chemotherapy in treating RET Fusion–Positive NSCLC and the use of Bispecific T-Cell Engager Tarlatamab in treating Small Cell Lung Cancer. A novel blood test for early cancer detection is showing potential. Crowdfunding campaigns are playing a significant role in covering medical expenses for cancer survivors. A drop in E-Cigarette use among High School Students has been observed. The impact of air pollution on breast cancer risk is being studied.